Medtronic, Inc. (MDT), Abbott Laboratories (ABT): Should You Trust This Top Health-Care Dividend?

These smaller but growing divisions are paving the way for Medtronic, Inc. (NYSE:MDT)’s bright future. Neuromodulation’s been an industry that many across the device industry are looking into: Boston Scientific Corporation (NYSE:BSX)‘s neuromodulation segment grew more than 14% in the first half of 2013 alone, and other companies also are seeing strong growth from this market. If Medtronic can continue tapping into this and other growth industries, it’ll be able to counter falling sales in some of its cardiovascular businesses until Medtronic can get those segments turned around.

The right outlook for income investors
Between advancing on high-growth businesses and pushing international growth into developing economies, Medtronic, Inc. (NYSE:MDT)’s setting investors up for strong years to come. The company’s always been among the most stable in the device industry because of its size and strength — attributes stability-seeking income investors won’t shy away from.

Coupled with a respectable dividend yield at a manageable payout ratio — along with an industry-topping history of dividend increases — Medtronic, Inc. (NYSE:MDT) is a stock no income investor could be criticized for taking a long look at.

The article Should You Trust This Top Health-Care Dividend? originally appeared on Fool.com.

Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. 

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.